Last reviewed · How we verify
Beraprost Sodium Tablets
Beraprost Sodium Tablets, marketed by Shenzhen People's Hospital, is a drug with a key composition patent expiring in 2028. The primary strength of Beraprost Sodium Tablets lies in its established market presence, leveraging the strong reputation of Shenzhen People's Hospital. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Beraprost Sodium Tablets |
|---|---|
| Sponsor | Shenzhen People's Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Protective Effect of Beraprost Sodium Tablets on Reperfusion Therapy for Acute STEMI (EARLY_PHASE1)
- Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH) (PHASE2)
- A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension (PHASE3)
- Beraprost-314d Added-on to Tyvaso® (BEAT) (PHASE3)
- A Multi-Center, Open-Label, Multiple Dose, Dose Finding Study Exploring the Safety and Tolerability of Beraprost Sodium Modified Release in PAH Patients (PHASE2)
- An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients (PHASE2)
- Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) Patients (PHASE2)
- Evaluation of Nail Fold Microcirculation in CKD (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |